JP6663438B2 - 癌および皮膚病変の治療 - Google Patents

癌および皮膚病変の治療 Download PDF

Info

Publication number
JP6663438B2
JP6663438B2 JP2017540976A JP2017540976A JP6663438B2 JP 6663438 B2 JP6663438 B2 JP 6663438B2 JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017540976 A JP2017540976 A JP 2017540976A JP 6663438 B2 JP6663438 B2 JP 6663438B2
Authority
JP
Japan
Prior art keywords
hpv
dose
vaccine
patient
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017540976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531699A5 (enExample
JP2017531699A (ja
Inventor
アイオナイデス ティム
アイオナイデス ティム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of JP2017531699A publication Critical patent/JP2017531699A/ja
Publication of JP2017531699A5 publication Critical patent/JP2017531699A5/ja
Application granted granted Critical
Publication of JP6663438B2 publication Critical patent/JP6663438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017540976A 2014-10-24 2015-10-23 癌および皮膚病変の治療 Active JP6663438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
US62/068,332 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (3)

Publication Number Publication Date
JP2017531699A JP2017531699A (ja) 2017-10-26
JP2017531699A5 JP2017531699A5 (enExample) 2018-11-15
JP6663438B2 true JP6663438B2 (ja) 2020-03-11

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540976A Active JP6663438B2 (ja) 2014-10-24 2015-10-23 癌および皮膚病変の治療

Country Status (15)

Country Link
US (1) US10238729B2 (enExample)
EP (1) EP3209676A4 (enExample)
JP (1) JP6663438B2 (enExample)
KR (1) KR102285401B1 (enExample)
CN (1) CN107001430A (enExample)
AU (1) AU2015335652B2 (enExample)
BR (1) BR112017008280A2 (enExample)
CA (1) CA2965498A1 (enExample)
CL (1) CL2017001008A1 (enExample)
IL (1) IL251825B2 (enExample)
MX (1) MX395186B (enExample)
MY (1) MY195018A (enExample)
PH (1) PH12017500754A1 (enExample)
SG (1) SG11201703262UA (enExample)
WO (1) WO2016065281A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60126737T2 (de) * 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
CN107252489A (zh) * 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
US9566323B2 (en) 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3054994A4 (en) 2013-10-13 2017-10-11 The Board of Trustees of the University of Arkansas Human papilloma virus therapeutic vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Also Published As

Publication number Publication date
EP3209676A1 (en) 2017-08-30
CN107001430A (zh) 2017-08-01
MY195018A (en) 2023-01-03
MX2017005418A (es) 2017-11-30
AU2015335652B2 (en) 2020-07-02
IL251825A0 (en) 2017-06-29
IL251825B1 (en) 2023-05-01
MX395186B (es) 2025-03-21
PH12017500754A1 (en) 2017-10-30
JP2017531699A (ja) 2017-10-26
KR102285401B1 (ko) 2021-08-02
US20160114023A1 (en) 2016-04-28
BR112017008280A2 (pt) 2018-01-02
AU2015335652A1 (en) 2017-05-25
US10238729B2 (en) 2019-03-26
SG11201703262UA (en) 2017-05-30
IL251825B2 (en) 2023-09-01
CA2965498A1 (en) 2016-04-28
KR20170072279A (ko) 2017-06-26
CL2017001008A1 (es) 2017-11-24
WO2016065281A1 (en) 2016-04-28
EP3209676A4 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
Abeck et al. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children
Stern et al. Therapy of human papillomavirus-related disease
Tsai Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine
Ding et al. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer
JP2023110038A (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
CN105597092A (zh) 含有白介素15的防治hpv感染的疫苗喷雾剂
KR102285401B1 (ko) 암 및 피부 병변 치료
JP2019506435A5 (enExample)
Shin et al. Nonavalent human papillomavirus vaccine for cutaneous warts: a retrospective study
HK1241898A1 (en) Cancer and skin lesion treatment
WO2007033533A1 (en) Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv
JP2017531699A5 (enExample)
Abdulsalam et al. Role of HPV vaccines in multiple recalcitrant warts treatment
Tezikov et al. Anogenital Warts: New Opportunities for Prevention
US20180250378A1 (en) Combination of therapeutic vaccine and pd-1-related blockade for treating human papillomavirus-associated diseases
WO2012097634A1 (zh) 一种治疗hpv感染的药物以及该药物在制备治疗hpv感染药物中的应用
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
Zawadka Human papilloma virus vaccination
Fruscalzo et al. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development
Protasov et al. Anogenital Warts: New Opportunities for Prevention and Treatment
Elliott Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9)
Abd Elfatah et al. Novel Guidelines for Immunotherapeutic Treatment Options of Genital Warts: Review article Novel Guidelines for Immunotherapeutic Treatment Options of Genital Warts
Jorge et al. Update: HPV prevention
JP2023546073A (ja) 第１の治療有効成分としてのワクチンを、第２の有効成分と組み合わせて使用する、癌を治療するための組成物及び方法
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200214

R150 Certificate of patent or registration of utility model

Ref document number: 6663438

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250